DK1103545T3 - 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide - Google Patents
2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramideInfo
- Publication number
- DK1103545T3 DK1103545T3 DK00125450T DK00125450T DK1103545T3 DK 1103545 T3 DK1103545 T3 DK 1103545T3 DK 00125450 T DK00125450 T DK 00125450T DK 00125450 T DK00125450 T DK 00125450T DK 1103545 T3 DK1103545 T3 DK 1103545T3
- Authority
- DK
- Denmark
- Prior art keywords
- isobutyramide
- morpholin
- pyridin
- tolyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99123685 | 1999-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1103545T3 true DK1103545T3 (da) | 2004-03-15 |
Family
ID=8239481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00125450T DK1103545T3 (da) | 1999-11-29 | 2000-11-21 | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
Country Status (50)
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1157006B1 (en) | 1999-02-24 | 2006-10-25 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
DK1394150T3 (da) * | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
IL153834A0 (en) * | 2000-07-14 | 2003-07-31 | Hoffmann La Roche | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
CN1625603A (zh) * | 2002-01-31 | 2005-06-08 | 弗·哈夫曼-拉罗切有限公司 | 前速激肽原基因中的遗传多态性 |
RU2347777C2 (ru) | 2003-07-03 | 2009-02-27 | Ф.Хоффманн-Ля Рош Аг | Двойные агонисты nk1/nk3 для лечения шизофрении |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
WO2006002860A1 (en) | 2004-07-06 | 2006-01-12 | F. Hoffmann-La Roche Ag | Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
EP2281556A1 (en) | 2005-02-25 | 2011-02-09 | F. Hoffmann-La Roche AG | Tablets with improved drugs substance dispersibility |
CA2602445C (en) * | 2005-03-23 | 2013-08-20 | F.Hoffmann-La Roche Ag | Metabolites for nk-i antagonists for emesis |
ES2335922T3 (es) | 2005-09-23 | 2010-04-06 | F.Hoffmann-La Roche Ag | Nueva formulacion de dosificacion. |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
WO2014150276A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2930008A1 (en) | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
KR101948238B1 (ko) | 2016-08-19 | 2019-02-14 | (주)케어젠 | 미녹시딜과 펩타이드의 결합체 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0533280B2 (en) * | 1991-09-20 | 2004-12-01 | Glaxo Group Limited | Novel medical use for tachykinin antagonists |
CA2099233A1 (en) * | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
DK0737192T3 (da) * | 1993-12-29 | 2001-11-26 | Merck Sharp & Dohme | Substituerede morpholinderivater og deres anvendelse som terapeutiske midler |
IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
ES2194937T3 (es) * | 1995-03-24 | 2003-12-01 | Takeda Chemical Industries Ltd | Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina. |
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
DK1394150T3 (da) * | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
IL153834A0 (en) * | 2000-07-14 | 2003-07-31 | Hoffmann La Roche | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
-
2000
- 2000-11-21 SI SI200030246T patent/SI1103545T1/xx unknown
- 2000-11-21 DK DK00125450T patent/DK1103545T3/da active
- 2000-11-21 ES ES00125450T patent/ES2208205T3/es not_active Expired - Lifetime
- 2000-11-21 DE DE60006340T patent/DE60006340T2/de not_active Expired - Lifetime
- 2000-11-21 TR TR2003/02077T patent/TR200302077T4/xx unknown
- 2000-11-21 AT AT00125450T patent/ATE253561T1/de active
- 2000-11-21 PT PT00125450T patent/PT1103545E/pt unknown
- 2000-11-21 EP EP00125450A patent/EP1103545B1/en not_active Expired - Lifetime
- 2000-11-23 AU AU71787/00A patent/AU775292B2/en not_active Expired
- 2000-11-23 NZ NZ508386A patent/NZ508386A/xx unknown
- 2000-11-23 YU YU73400A patent/YU73400A/sh unknown
- 2000-11-23 PE PE2000001254A patent/PE20010901A1/es not_active Application Discontinuation
- 2000-11-23 IL IL139868A patent/IL139868A/en active IP Right Grant
- 2000-11-23 JO JO2000187A patent/JO2298B1/en active
- 2000-11-23 GB GB0028566A patent/GB2356863A/en not_active Withdrawn
- 2000-11-23 CA CA002326529A patent/CA2326529C/en not_active Expired - Lifetime
- 2000-11-24 IS IS5725A patent/IS2212B/is unknown
- 2000-11-24 DE DE10058310A patent/DE10058310A1/de not_active Withdrawn
- 2000-11-24 PA PA20008507201A patent/PA8507201A1/es unknown
- 2000-11-24 FR FR0015193A patent/FR2801590A1/fr not_active Withdrawn
- 2000-11-24 SG SG200006945A patent/SG97171A1/en unknown
- 2000-11-24 JP JP2000356833A patent/JP3480835B2/ja not_active Expired - Lifetime
- 2000-11-24 HR HR20000809A patent/HRP20000809A2/hr not_active Application Discontinuation
- 2000-11-24 CZ CZ20004399A patent/CZ299286B6/cs not_active IP Right Cessation
- 2000-11-26 GC GCP20001052 patent/GC0000151A/xx active
- 2000-11-27 ZA ZA200006964A patent/ZA200006964B/xx unknown
- 2000-11-27 HU HU0004725A patent/HU224703B1/hu active IP Right Grant
- 2000-11-27 SK SK1793-2000A patent/SK285373B6/sk unknown
- 2000-11-27 MY MYPI20005527A patent/MY127426A/en unknown
- 2000-11-27 GE GEAP20005644A patent/GEP20022763B/en unknown
- 2000-11-27 MX MXPA00011672A patent/MXPA00011672A/es active IP Right Grant
- 2000-11-27 AR ARP000106217A patent/AR033659A1/es unknown
- 2000-11-27 CO CO00090625A patent/CO5251405A1/es active IP Right Grant
- 2000-11-28 GT GT200000197A patent/GT200000197A/es unknown
- 2000-11-28 SV SV2000000227A patent/SV2002000227A/es unknown
- 2000-11-28 UY UY26458A patent/UY26458A1/es not_active Application Discontinuation
- 2000-11-28 BG BG104992A patent/BG64622B1/bg unknown
- 2000-11-28 UA UA2000116781A patent/UA70326C2/uk unknown
- 2000-11-28 NO NO20006012A patent/NO317264B1/no not_active IP Right Cessation
- 2000-11-28 KR KR10-2000-0071141A patent/KR100390117B1/ko active IP Right Grant
- 2000-11-28 ES ES200002839A patent/ES2171134A1/es not_active Withdrawn
- 2000-11-28 PL PL344147A patent/PL195957B1/pl unknown
- 2000-11-28 BR BRPI0005616A patent/BRPI0005616B8/pt not_active IP Right Cessation
- 2000-11-28 DO DO2000000106A patent/DOP2000000106A/es unknown
- 2000-11-28 EA EA200001114A patent/EA004404B1/ru not_active IP Right Cessation
- 2000-11-28 MA MA26111A patent/MA26754A1/fr unknown
- 2000-11-29 OA OA1200000324A patent/OA11513A/fr unknown
- 2000-11-29 IT IT2000MI002575A patent/IT1320120B1/it active
- 2000-11-29 TN TNTNSN00226A patent/TNSN00226A1/fr unknown
- 2000-11-29 CN CNB001342606A patent/CN1152016C/zh not_active Expired - Lifetime
- 2000-11-29 ID IDP20001029D patent/ID28483A/id unknown
-
2001
- 2001-11-06 HK HK01107733A patent/HK1036759A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1103545T3 (da) | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide | |
PT1056759E (pt) | Derivados do 2-(purin-9-il)-tetrahidrofurano-3,4-diolc | |
ID29609A (id) | Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol | |
ID28219A (id) | Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol | |
ATE363463T1 (de) | 2-(2,6-dichlorphenyl)-diarylimidazole | |
DE60012154D1 (de) | Zange | |
ATE303388T1 (de) | Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate | |
NO993823D0 (no) | 2-Amino-6-(2-substituert-4-fenoksy)-substituerte pyridiner | |
DK1480983T3 (da) | Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater | |
ATE313527T1 (de) | 4-benzyl-1-(2-(4-hydroxy-phenoxy)-ethyl)- piperidin-3,4-diol | |
NO20040404L (no) | 2- (3,5-bis-trifluorometyl-fenyl) - N - [6-(1,1-diokso-1lam bda6-tiomorfolin-4-yl) - 4 - (2-metyl- eller 4-fluor-2-metylsubstituert) fenyl-pyridin-3-yl] -N-metyl-isobutyrami. | |
DE50006616D1 (de) | Zange | |
NO20042980L (no) | 3,4-dihydro-1H-isokinolin-2-yl-derivater | |
DE50003869D1 (de) | Kalander | |
ATE525362T1 (de) | 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4- | |
DE50005314D1 (de) | Kalander | |
DE50005755D1 (de) | Kalander | |
DE50007005D1 (de) | Kalander | |
IS7131A (is) | Nýjar 2,4-díamínóþíasól afleiður | |
IL159571A0 (en) | 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1,-DIOXO-1lamda6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED) PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE | |
FI990794A (fi) | Kalanteri | |
DE10085027T1 (de) | Kalander | |
FI20001539A0 (fi) | Monitelakalanteri | |
ITRM20000220A0 (it) | Cinnamilidenidrazide isonicotinica c15h13n3o | |
PT1065205E (pt) | Derivados heteroaromaticos |